nuclear receptor subfamily 1 group I member 3Genealiases: CAR · CAR1 · MB67
Q-omics provides the consensus-scored NR1I3 profile across patient tissues and cancer cell-line models. NR1I3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NR1I3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NR1I3 RNA expression shows 18,224 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where NR1I3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NR1I3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NR1I3 survival associations across molecular data types. NR1I3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NR1I3 RNA expression–survival associations across cancer types. High NR1I3 expression shows unfavorable associations in ACC, BRCA, UCEC, CHOL and LUAD, but favorable associations in SARC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NR1I3 RNA expression.
This table summarizes NR1I3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NR1I3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NR1I3 shows lower tumor expression in KIRC, KIRP, THCA, KICH, CHOL and LIHC. The KIRC box plot shows higher NR1I3 RNA expression in normal versus tumor tissue (log2 FC = −1.297, t-test p < 0.001).
This table shows molecular features associated with NR1I3 in patient tissues and cancer cell lines. In patient samples, NR1I3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NR1I3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
